(5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoyl chloride

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 酰卤
• 英文名称: (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoyl chloride
• 化学式: C₂₀H₃₁ClO
• 分子量: 322.9
• InChiKey: NTBLHFFUSJRJQO-CGRWFSSPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.3
• 重原子数：
  22
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (2S,3R,4R,5R,6R)-2-[(2R,3S,4R,5R,6R)-6-[(E,2S,3R)-2-amino-3-hydroxyoctadec-4-enoxy]-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol 、 (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoyl chloride 生成 (5E,8E,11E,14E)-N-[(E,2S,3R)-1-[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2S,3R,4R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyoctadec-4-en-2-yl]icosa-5,8,11,14-tetraenamide
  参考文献：
  名称：

  SCHMIDT, RICHARD R.;BAR, THOMAS;APELL, HANS-JUERGEN, ANGEW. CHEM., 99,(1987) N 8, 813-814

  摘要：

  DOI：
• 作为产物：
  描述：

  5,8,11,14-eicosatetraenoic acid 、 草酰氯 生成 (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoyl chloride
  参考文献：
  名称：

  XIBINO, XIDEHXIKO;IVASAKI, XIROSI;NAKATI, OSAMU

  摘要：

  DOI：

文献信息

• Compositions containing insaturated fatty acids and an aldose reductase inhibitor for treatment of diabetic complications
  申请人：SCOTIA HOLDINGS PLC

  公开号：EP0694302A1

  公开（公告）日：1996-01-31

  Use of 6-desaturated n-6 fatty acids, especially gammalinolenic acid (GLA), dihomogammalinolenic acid (DGLA) or arachidonic acid (AA), together with a pharmaceutically acceptable material reducing intracellular levels of sorbitol in the body, particularly an aldose reductase inhibitor, in the treatment of (including prophylactic treatment), and in the preparation of medicaments for the treatment of (including prophylactic treatment), the long-term complications of diabetes mellitus. Pharmaceutical compositions of said materials. The ascorbate esters of 6-desaturated n-6 fatty acids (other than GLA or DGLA) per se.

  将 6-不饱和 n-6 脂肪酸，特别是丙三酸（GLA）、二氢丙三酸（DGLA）或花生四烯酸（AA），连同可降低细胞内山梨醇水平的药学上可接受的物质，特别是醛糖还原酶抑制剂，用于治疗（包括预防性治疗）糖尿病的长期并发症，以及制备治疗（包括预防性治疗）糖尿病的药物。上述材料的药物组合物。6- 不饱和 n-6 脂肪酸（GLA 或 DGLA 除外）的抗坏血酸酯本身。
• US6069168A
  申请人：——

  公开号：US6069168A

  公开（公告）日：2000-05-30
• [EN] METHODS FOR THE AMELIORATION OF NEUROPSYCHIATRIC DISORDERS BY INHIBITING THE INACTIVATING TRANSPORT OF ENDOGENOUS CANNABINOID SUBSTANCES<br/>[FR] PROCEDES D'AMELIORATION DE TROUBLES NEUROPSYCHIATRIQUES PAR INHIBITION DU TRANSPORT INACTIVANT DE SUBSTANCES CANNABINOIDES ENDOGENES
  申请人：UNIV CALIFORNIA

  公开号：WO2001001980A1

  公开（公告）日：2001-01-11

  The invention is directed to a method for ameliorating a neuropsychiatric disorder in a patient by inhibiting the inactivating transport of an endogenous cannabinoid substance. The method comprises administration of a pharmaceutical composition able to inhibit the transport of an endogenous cannabinoid substance into cells. The administration is in an amount sufficient to inhibit the inactivating transport of an endogenous cannabinoid substance and to ameliorate the neuropsychiatric disorder in the patient.